Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

被引：0

作者：

Konstantin Huhn

Antonios Bayas

Sebastian Doerck

Benedikt Frank

Kathrin Gerbershagen

Kerstin Hellwig

Boris Kallmann

Christoph Kleinschnitz

Ingo Kleiter

De-Hyung Lee

Volker Limmroth

Mathias Mäurer

Sven Meuth

Peter Rieckmann

Tobias Ruck

Ralf Gold

Ralf A. Linker

机构：

[1] Friedrich-Alexander-University,Department of Neurology, University Hospital Erlangen

[2] Klinikum Augsburg,Department of Neurology

[3] Julius-Maximilians-University Würzburg,Department of Neurology

[4] University Hospital Essen,Department of Neurology

[5] Klinikum Köln-Merheim,Department of Neurology

[6] St. Josef-Hospital/Ruhr-University Bochum,Department of Neurology

[7] MS Center Bamberg,Department of Neurology

[8] Caritas Krankenhaus Bad Mergentheim,Department of Translational Neurology

[9] University Hospital Münster,Department of Neurology

[10] Julius-Spital Würzburg,undefined

[11] Marianne-Strauß-Klinik,undefined

[12] Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH,undefined

[13] Medical Park Klinik Loipl,undefined

来源：

Journal of Neurology | 2018年 / 265卷

关键词：

Alemtuzumab; Fingolimod; Multiple sclerosis; Disease-modifying treatment;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1521 / 1527

页数：6

共 50 条

[1] Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study
Huhn, Konstantin
Bayas, Antonios
Doerck, Sebastian
Frank, Benedikt
Gerbershagen, Kathrin
Hellwig, Kerstin
Kallmann, Boris
Kleinschnitz, Christoph
Kleiter, Ingo
Lee, De-Hyung
Limmroth, Volker
Maeurer, Mathias
Meuth, Sven
Rieckmann, Peter
Ruck, Tobias
Gold, Ralf
Linker, Ralf A.
JOURNAL OF NEUROLOGY, 2018, 265 (07) : 1521 - 1527
[2] Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study
Jessica Frau
Francesco Saccà
Alessio Signori
Damiano Baroncini
Giuseppe Fenu
Pietro Annovazzi
Marco Capobianco
Elisabetta Signoriello
Alice Laroni
Sara La Gioia
Arianna Sartori
Giorgia Teresa Maniscalco
Simona Bonavita
Marinella Clerico
Cinzia Valeria Russo
Antonio Gallo
Caterina Lapucci
Antonio Carotenuto
Maria Pia Sormani
Eleonora Cocco
Journal of Neurology, 2019, 266 : 2440 - 2446
[3] Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study
Frau, Jessica
Sacca, Francesco
Signori, Alessio
Baroncini, Damiano
Fenu, Giuseppe
Annovazzi, Pietro
Capobianco, Marco
Signoriello, Elisabetta
Laroni, Alice
La Gioia, Sara
Sartori, Arianna
Maniscalco, Giorgia Teresa
Bonavita, Simona
Clerico, Marinella
Russo, Cinzia Valeria
Gallo, Antonio
Lapucci, Caterina
Carotenuto, Antonio
Sormani, Maria Pia
Cocco, Eleonora
JOURNAL OF NEUROLOGY, 2019, 266 (10) : 2440 - 2446
[4] Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center
P. Rodríguez de Vera Gómez
J. J. García-González
R. Ravé-García
R. López Ruiz
A. Torres-Cuadro
S. Eichau-Madueño
C. García-García
T. Martín-Hernández
Journal of Endocrinological Investigation, 2022, 45 : 1977 - 1990
[5] Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center
Rodriguez de Vera Gomez, P.
Garcia-Gonzalez, J. J.
Rave-Garcia, R.
Lopez Ruiz, R.
Torres-Cuadro, A.
Eichau-Madueno, S.
Garcia-Garcia, C.
Martin-Hernandez, T.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (10) : 1977 - 1990
[6] Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study
Lapucci, Caterina
Frau, Jessica
Cocco, Eleonora
Coghe, Giancarlo
Petracca, Maria
Lanzillo, Roberta
Morra, Vincenzo Brescia
Nicoletti, Carolina Gabri
Landi, Doriana
Marfia, Girolama
Vercellino, Marco
Cavalla, Paola
Bianco, Assunta
Mirabella, Massimiliano
Clerici, Valentina Torri
Tomas, Eugenia
Ferro, Maria Teresa
Grossi, Paola
Nozzolillo, Agostino
Moiola, Lucia
Zaffaroni, Mauro
Ronzoni, Marco
Pinardi, Federica
Novi, Giovanni
Cellerino, Maria
Uccelli, Antonio
Inglese, Matilde
MULTIPLE SCLEROSIS JOURNAL, 2024,
[7] Efficacy and safety of Fingolimod therapy in multi-ethnic Malaysian patients with relapsing remitting multiple sclerosis: A longitudinal observational study
Viswanathan, S.
JOURNAL OF CLINICAL NEUROSCIENCE, 2018, 54 : 25 - 28
[8] An observational study of alemtuzumab-treated relapsing MS patients at the UBC MS Clinic
Yong, H. Y. F.
Beauchemin, P.
Barclay, K.
Devonshire, V.
Sayao, A. -L.
Carruthers, R.
Traboulsee, A.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 328 - 329
[9] Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study
Narayana, Ponnada A.
Govindarajan, Koushik A.
Goel, Priya
Datta, Sushmita
Lincoln, John A.
Cofield, Stacy S.
Cutter, Gary R.
Lublin, Fred D.
Wolinsky, Jerry S.
NEUROIMAGE-CLINICAL, 2013, 2 : 120 - 131
[10] Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Kalincik, Tomas
Brown, J. William L.
Robertson, Neil
Willis, Mark
Scolding, Neil
Rice, Claire M.
Wilkins, Alastair
Pearson, Owen
Ziemssen, Tjalf
Hutchinson, Michael
McGuigan, Christopher
Jokubaitis, Vilija
Spelman, Tim
Horakova, Dana
Havrdova, Eva
Trojano, Maria
Izquierdo, Guillermo
Lugaresi, Alessandra
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Grammond, Pierre
Alroughani, Raed
Pucci, Eugenio
Sola, Patrizia
Hupperts, Raymond
Lechner-Scott, Jeannette
Terzi, Murat
Van Pesch, Vincent
Rozsa, Csilla
Grand'Maison, Francois
Boz, Cavit
Granella, Franco
Slee, Mark
Spitaleri, Daniele
Olascoaga, Javier
Bergamaschi, Roberto
Verheul, Freek
Vucic, Steve
McCombe, Pamela
Hodgkinson, Suzanne
Sanchez-Menoyo, Jose Luis
Ampapa, Radek
Simo, Magdolna
Csepany, Tunde
Ramo, Cristina
Cristiano, Edgardo
Barnett, Michael
Butzkueven, Helmut
Coles, Alasdair
LANCET NEUROLOGY, 2017, 16 (04): : 271 - 281

← 1 2 3 4 5 →